Recent Company News

• 07:33 AM ET Nov 17, 2025
  

  Brainsway launches trial of Deep TMS 360 System for Alcohol Use Disorder ($15.76, 0.00)

• 09:16 AM ET Nov 13, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:24 AM ET Nov 11, 2025
  

  StreetAccount Summary - US Pre-market trading

• 06:04 AM ET Nov 13, 2025
  

  BrainsWay receives FDA clearance of Deep TMS as adjunct therapy for major depressive disorder (MDD) in adolescents aged 15 to 21 ($15.78, 0.00)

• 11:33 AM ET Nov 11, 2025
  

  Transcript Intelligence: Brainsway Q3 Earnings Guidance ($14.97, -1.16)

• 11:33 AM ET Nov 11, 2025
  

  Transcript Intelligence: Brainsway Q3 Earnings Themes ($14.97, -1.16)

• 11:33 AM ET Nov 11, 2025
  

  Transcript Intelligence: Brainsway Q3 Earnings Q&A ($14.97, -1.16)

• 07:35 AM ET Nov 11, 2025
  

  Brainsway reports Q3 EPS $0.04 vs FactSet $0.05 [3 est, $0.03-0.06] ($16.12, 0.00)

• 08:15 AM ET Nov 04, 2025
  

  BrainsWay reports NIH grant to U.S. research team investigating accelerated Deep TMS for treatment of alcohol use disorder ($17.38, 0.00)